NovartisNVS
NVS
About: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Employees: 76,057
0
Funds holding %
of 6,780 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.6% less ownership
Funds ownership: 6.62% [Q2] → 6.02% (-0.6%) [Q3]
1% less funds holding
Funds holding: 1,292 [Q2] → 1,283 (-9) [Q3]
2% less capital invested
Capital invested by funds: $15.4B [Q2] → $15.2B (-$266M) [Q3]
8% less first-time investments, than exits
New positions opened: 99 | Existing positions closed: 108
13% less funds holding in top 10
Funds holding in top 10: 15 [Q2] → 13 (-2) [Q3]
15% less repeat investments, than reductions
Existing positions increased: 401 | Existing positions reduced: 473
42% less call options, than puts
Call options by funds: $171M | Put options by funds: $294M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$120
15%
upside
Avg. target
$124
18%
upside
High target
$130
24%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
BMO Capital Etzer Darout 54% 1-year accuracy 15 / 28 met price target | 15%upside $120 | Market Perform Maintained | 30 Oct 2024 |
B of A Securities Graham Perry 0 / 0 met price target | 24%upside $130 | Neutral Downgraded | 11 Sept 2024 |
Goldman Sachs James Quigley 0 / 0 met price target | 16%upside $121 | Neutral Downgraded | 5 Sept 2024 |
Financial journalist opinion
Based on 25 articles about NVS published over the past 30 days
Positive
Seeking Alpha
20 hours ago
Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
Olema Pharmaceuticals, Inc. entered into an agreement with Novartis to obtain KISQALI supply for the soon-to-be initiated phase 3 OPERA-02 study, targeting patients with ER+/HER2- metastatic breast cancer; Study to start mid-2025. Data from ongoing phase 3 OPERA-01 study, using palazestrant alone as a monotherapy to target patients with ER+/HER2- metastatic breast cancer, expected in 2026. The global breast cancer market size is predicted to surpass $89.01 billion by 2034.
Positive
Benzinga
23 hours ago
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecules.
Positive
Reuters
1 day ago
PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis
PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological disorder.
Neutral
PRNewsWire
1 day ago
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
- PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales - - Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study - - PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- WARREN, N.J. , Dec. 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington's disease program, which includes related molecules.
Positive
The Motley Fool
1 day ago
2 Dividend Stocks to Buy and Hold Forever
No income investor buys shares of a dividend-paying company expecting that it will suspend its distributions at some point. Quite the contrary, dividend investors want those payouts to keep going and growing for as long as possible -- preferably forever.
Positive
Zacks Investment Research
4 days ago
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.
Neutral
GlobeNewsWire
6 days ago
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
Basel, November 27, 2024 – Novartis announced today that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence1 ,7.
Neutral
GlobeNewsWire
1 week ago
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
Basel, November 25, 2024 – Novartis will present data from more than 65 abstracts, including investigator-initiated trials at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition and the 2024 San Antonio Breast Cancer Symposium® (SABCS).
Positive
Zacks Investment Research
1 week ago
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.
Neutral
Reuters
1 week ago
Novartis: launch of Morphosys drug by could be 2027 or later
Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data.
Charts implemented using Lightweight Charts™